DE60033932D1 - Methode und zusammensetzung zur inhibierung von kardiovaskulärer zellproliferation - Google Patents

Methode und zusammensetzung zur inhibierung von kardiovaskulärer zellproliferation

Info

Publication number
DE60033932D1
DE60033932D1 DE60033932T DE60033932T DE60033932D1 DE 60033932 D1 DE60033932 D1 DE 60033932D1 DE 60033932 T DE60033932 T DE 60033932T DE 60033932 T DE60033932 T DE 60033932T DE 60033932 D1 DE60033932 D1 DE 60033932D1
Authority
DE
Germany
Prior art keywords
subunits
cell proliferation
composition
cardiovascular cell
arginine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60033932T
Other languages
English (en)
Other versions
DE60033932T2 (de
Inventor
John P Cooke
Garrison C Fathman
Jonathan B Rothbard
Shiro Uemura
Robert C Robbins
Murray H Kown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of DE60033932D1 publication Critical patent/DE60033932D1/de
Application granted granted Critical
Publication of DE60033932T2 publication Critical patent/DE60033932T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/06—Use of macromolecular materials
    • A61L33/12—Polypeptides, proteins or derivatives thereof, e.g. degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/06—Use of macromolecular materials
    • A61L33/12—Polypeptides, proteins or derivatives thereof, e.g. degradation products thereof
    • A61L33/128—Other specific proteins or polypeptides not covered by A61L33/122 - A61L33/126
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
DE60033932T 1999-06-05 2000-06-05 Methode und zusammensetzung zur inhibierung von kardiovaskulärer zellproliferation Expired - Lifetime DE60033932T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13782699P 1999-06-05 1999-06-05
US137826P 1999-06-05
PCT/US2000/040125 WO2000074701A2 (en) 1999-06-05 2000-06-05 Method and composition for inhibiting cardiovascular cell proliferation

Publications (2)

Publication Number Publication Date
DE60033932D1 true DE60033932D1 (de) 2007-04-26
DE60033932T2 DE60033932T2 (de) 2007-12-06

Family

ID=22479193

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60033932T Expired - Lifetime DE60033932T2 (de) 1999-06-05 2000-06-05 Methode und zusammensetzung zur inhibierung von kardiovaskulärer zellproliferation

Country Status (10)

Country Link
US (5) US6605115B1 (de)
EP (1) EP1189623B1 (de)
JP (1) JP2003501393A (de)
AT (1) ATE356629T1 (de)
AU (1) AU774185B2 (de)
CA (1) CA2376375C (de)
DE (1) DE60033932T2 (de)
IL (1) IL141250A0 (de)
MX (1) MXPA01001297A (de)
WO (1) WO2000074701A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1175210A4 (de) 1999-03-19 2003-07-09 Enos Pharmaceuticals Inc Verbesserung der bioverfügbarkeit von arzneimitteln im hirn
CA2376375C (en) * 1999-06-05 2011-07-12 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for inhibiting cardiovascular cell proliferation
DE69930150T2 (de) 1999-12-21 2006-11-30 Korea Green Cross Corp., Yongin Arginin-reiche anti-vaskuläre endotheliale wachstumsfaktor-peptide,welche wachstum und metastase humaner tumorzellen durch blockierung der angiogenese inhibieren
JP2005508832A (ja) * 2001-02-16 2005-04-07 セルゲイト， インコーポレイテッド 間隔を開けてアルギニン部分を含むトランスポーター
MXPA04001142A (es) 2001-08-03 2004-09-13 Univ Leland Stanford Junior Sintesis bidireccional de agentes de transporte de oligoguanidina.
WO2003020260A1 (en) * 2001-08-31 2003-03-13 Metaproteomics, Llc Arginine compositions for coordinate modification of multiple cardiovascular risk factors
JP4229842B2 (ja) * 2002-02-22 2009-02-25 ルバンス セラピュティックス インク． Ｌ−アルギニンオリゴマーを含む化粧品処方
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
US6969514B2 (en) 2003-02-05 2005-11-29 Soll David B Method for treating elevated intraocular pressure, including glaucoma
US7553326B2 (en) * 2003-11-24 2009-06-30 Sweet Richard M Method and apparatus for preventing dialysis graft intimal hyperplasia
WO2005084301A2 (en) * 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
US9309347B2 (en) 2009-05-20 2016-04-12 Biomedical, Inc. Bioresorbable thermoset polyester/urethane elastomers
US8992601B2 (en) 2009-05-20 2015-03-31 480 Biomedical, Inc. Medical implants
US8888840B2 (en) * 2009-05-20 2014-11-18 Boston Scientific Scimed, Inc. Drug eluting medical implant
US20110319987A1 (en) 2009-05-20 2011-12-29 Arsenal Medical Medical implant
US8137396B2 (en) * 2009-05-20 2012-03-20 480 Biomedical, Inc Medical implant
US9265633B2 (en) 2009-05-20 2016-02-23 480 Biomedical, Inc. Drug-eluting medical implants
US8372133B2 (en) * 2009-10-05 2013-02-12 480 Biomedical, Inc. Polymeric implant delivery system
WO2011139714A2 (en) 2010-04-26 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
CN103096911B (zh) 2010-04-27 2018-05-29 Atyr 医药公司 与异亮氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
WO2011150279A2 (en) 2010-05-27 2011-12-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
CN103097523B (zh) 2010-04-29 2016-09-28 Atyr医药公司 与天冬酰胺酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
AU2011248457B2 (en) 2010-04-29 2017-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl tRNA synthetases
US8981045B2 (en) 2010-05-03 2015-03-17 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases
US8961961B2 (en) 2010-05-03 2015-02-24 a Tyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related protein fragments of arginyl-tRNA synthetases
CN105820252B (zh) 2010-05-03 2020-07-21 Atyr 医药公司 与苯丙氨酰-α-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US9114235B2 (en) 2010-05-03 2015-08-25 Cardiovascular Systems, Inc. Therapeutic agent delivery system and method for localized application of therapeutic substances to a biological lumen
CA2798139C (en) 2010-05-04 2019-09-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
CN103200953B (zh) 2010-05-14 2017-02-15 Atyr 医药公司 与苯丙氨酰‑β‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
EP2575857B1 (de) 2010-06-01 2018-01-24 aTyr Pharma, Inc. Innovative erkennung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen in zusammenhang mit proteinfragmenten von lysyl-trna-synthetasen
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
CN103108650A (zh) 2010-08-25 2013-05-15 Atyr医药公司 与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
EP3063168B1 (de) * 2013-10-30 2019-03-06 University of Western Australia Neuroprotektive peptide
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
DK3149025T3 (da) 2014-05-21 2019-07-22 Entrada Therapeutics Inc Cellepenetrerende peptider og fremgangsmåder til frembringelse og anvendelse deraf
WO2016033368A1 (en) 2014-08-27 2016-03-03 Ohio State Innovation Foundation Improved peptidyl calcineurin inhibitors
US20170114093A1 (en) * 2015-05-29 2017-04-27 Andrew Peter Mallon Methods of Treatment and Prevention of Disease by Arginine-rich Compositions that Induce Cytoprotection and Neuroprotection
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
EP3749365A4 (de) 2018-01-29 2022-01-12 Ohio State Innovation Foundation Peptidylinhibitoren der calcineurin-nfat-interaktion
EP3755351A4 (de) 2018-02-22 2021-11-24 Entrada Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von mitochondrialer neurogastrointestinaler enzephalopathie
KR102167755B1 (ko) 2018-05-23 2020-10-19 주식회사 큐어바이오 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
WO2020163654A1 (en) * 2019-02-06 2020-08-13 Paul Leo Mcgrane Biologically modified vascular grafts for improved bypass surgery outcomes

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2878124A (en) * 1956-03-10 1959-03-17 Bayer Ag Food additives
US3015567A (en) * 1959-03-20 1962-01-02 Du Pont Process for enriching the l-lysine content of food and the resulting product
US3360374A (en) * 1965-07-27 1967-12-26 Courtland Lab Process for making a dietary food product
US4029773A (en) * 1973-05-25 1977-06-14 Syntex (U.S.A.) Inc. Composition and method of treating ulcers
US3970750A (en) * 1974-10-08 1976-07-20 Sandoz, Inc. Effervescent potassium chloride composition
US4168307A (en) * 1974-11-08 1979-09-18 Mitsubishi Chemical Industries Limited N2 -Naphthalenesulfonyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof
ZA773318B (en) * 1976-06-18 1978-04-26 I Kleinberg Means and method for improving natural defenses against caries
US4847240A (en) * 1978-01-16 1989-07-11 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US4340592A (en) * 1980-03-14 1982-07-20 Adibi Siamak A Nutrient compositions and method of administering the same
US5334617A (en) * 1984-03-19 1994-08-02 The Rockefeller University Amino acids useful as inhibitors of the advanced glycosylation of proteins
US5034377A (en) * 1984-11-19 1991-07-23 Montefiore Hospital Association Of Western Pennsylvania Aqueous nutrient compositions comprising oligopeptides
EP0215805A1 (de) * 1985-01-18 1987-04-01 MERCK PATENT GmbH Immunoregulatorische peptide
NO166836C (no) * 1985-03-14 1991-09-11 Univ California Fremgangsmaate for behandling av et organtransplantat.
US4683291A (en) * 1985-10-28 1987-07-28 Scripps Clinic And Research Foundation Platelet binding inhibitors
GB8603171D0 (en) * 1986-02-08 1986-03-12 Howard A N Dietary product
US5248688A (en) * 1986-09-10 1993-09-28 Dudrick Medical Research Fund I, Ltd. Method and substrate composition for treating atherosclerosis
US5032608A (en) * 1986-09-10 1991-07-16 Dudrick Stanley J Method and substrate composition for treating atherosclerosis
US4920098A (en) * 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
US5041429A (en) * 1988-06-01 1991-08-20 Sanwa Kagaku Kenkyusho Co., Ltd. Cell activators, circulatory ameliorators and edible compositions
DE3819779A1 (de) * 1988-06-10 1989-12-21 Bayer Ag Verbessertes chromoxidgruen, verfahren zu seiner herstellung und dessen verwendung
DE68905387T2 (de) * 1988-06-22 1993-10-21 Morishita Pharma Aminosäure-Nahrungsmittelzusammensetzungen.
US4954526A (en) * 1989-02-28 1990-09-04 The United States Of America As Represented By The Department Of Health And Human Services Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents
CA1335361C (en) * 1989-05-24 1995-04-25 Andrei Z. Budzynski Thrombus-targeted complexes of plasminogen activator and fibrin fragments
US4957938A (en) * 1989-06-21 1990-09-18 Abbott Laboratories Nutritional formulation for the treatment of renal disease
US5380945A (en) * 1989-06-21 1995-01-10 Abbott Laboratories Guanidino compounds as regulators of nitric oxide synthase
US5464644A (en) * 1989-09-27 1995-11-07 Kellogg Company Ready-to-eat-cereal containing psyllium and use thereof for lowering cholesterol levels
US5157022A (en) * 1989-11-22 1992-10-20 Adrian Barbul Method for reducing blood cholesterol using arginine
JP2960947B2 (ja) * 1989-12-25 1999-10-12 日清製粉株式会社 脂質分解酵素阻害剤
US5576351A (en) * 1989-12-29 1996-11-19 Mcgaw, Inc. Use of arginine as an immunostimulator
EP0441119A3 (en) * 1990-01-09 1992-10-14 Richard D. Levere The use of l-arginine in the treatment of hypertension and other vascular disorders
US5236413B1 (en) * 1990-05-07 1996-06-18 Andrew J Feiring Method and apparatus for inducing the permeation of medication into internal tissue
WO1991018593A1 (en) * 1990-05-16 1991-12-12 Board Of Regents, The University Of Texas System Formula and method for the prevention and treatment of hypercholesterolemia and cellular hyperproliferative disorders
US5278189A (en) * 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
US5650418A (en) * 1990-06-04 1997-07-22 Therapy 2000 Therapeutic lysine salt composition and method of use
ATE123658T1 (de) * 1990-06-15 1995-06-15 Cortrak Medical Inc Vorrichtung zur abgabe von medikamenten.
US5499971A (en) * 1990-06-15 1996-03-19 Cortrak Medical, Inc. Method for iontophoretically delivering drug adjacent to a heart
US5106836A (en) * 1991-02-22 1992-04-21 Clintec Nutrition Co. Enteral diet
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
US5385937A (en) * 1991-04-10 1995-01-31 Brigham & Women's Hospital Nitrosation of homocysteine as a method for treating homocysteinemia
US5318531A (en) * 1991-06-11 1994-06-07 Cordis Corporation Infusion balloon catheter
JP2702322B2 (ja) * 1991-08-08 1998-01-21 フジックス株式会社 活性アミノ酸カルシウム、およびそれを含有する飲料、ならびにその製造方法
US5374651A (en) * 1991-09-27 1994-12-20 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives
US5262435A (en) * 1992-02-10 1993-11-16 Merck & Co., Inc. Cholesterol lowering compounds
US5221668A (en) * 1992-02-26 1993-06-22 Abbott Laboratories Nutritional product for trauma and surgery patients
US5348755A (en) * 1992-03-04 1994-09-20 Calgon Carbon Corporation Extension of edible oil lifetime using activated carbons
US5780039A (en) * 1992-04-23 1998-07-14 Novartis Nutrition Ag Orally-ingestible nutrition compositions having improved palatability
US5380487A (en) * 1992-05-05 1995-01-10 Pasteur Sanofi Diagnostics Device for automatic chemical analysis
EP0641183B1 (de) * 1992-05-29 2001-10-31 The Regents Of The University Of California Beschichtetes transplantat sowie herstellungsverfahren dafür
US5405919A (en) * 1992-08-24 1995-04-11 The United States Of America As Represented By The Secretary Of Health And Human Services Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders
US5830848A (en) * 1992-10-09 1998-11-03 The Regents Of The University Of California Method and agents for inducement of endogenous nitric oxide synthase for control and management of labor during pregnancy
US5385940A (en) * 1992-11-05 1995-01-31 The General Hospital Corporation Treatment of stroke with nitric-oxide releasing compounds
US5628782A (en) * 1992-12-11 1997-05-13 W. L. Gore & Associates, Inc. Method of making a prosthetic vascular graft
US5326569A (en) * 1992-12-23 1994-07-05 Abbott Laboratories Medical foods for the nutritional support of child/adult metabolic diseases
US5428070A (en) * 1993-06-11 1995-06-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5945452A (en) * 1993-06-11 1999-08-31 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
US5861168A (en) * 1993-06-11 1999-01-19 The Board Of Trustees Of The Leland Stanford Junior University Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
US5852058A (en) * 1993-06-11 1998-12-22 The Board Of Trustees Of The Leland Stanford Junior University Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
US5895783A (en) * 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
US6255277B1 (en) * 1993-09-17 2001-07-03 Brigham And Women's Hospital Localized use of nitric oxide-adducts to prevent internal tissue damage
JP3110931B2 (ja) * 1993-12-28 2000-11-20 第一製薬株式会社 平滑筋細胞増殖抑制作用を有するアルガトロバン製剤
US5482925A (en) * 1994-03-17 1996-01-09 Comedicus Incorporated Complexes of nitric oxide with cardiovascular amines as dual acting cardiovascular agents
US5626883A (en) * 1994-04-15 1997-05-06 Metagenics, Inc. Ascorbic acid compositions providing enhanced human immune system activity
US5576287A (en) * 1994-04-29 1996-11-19 Wake Forest University Method for treating acute renal disease and failure
US5643712A (en) * 1994-05-20 1997-07-01 Brasile; Lauren Method for treating and rendering grafts nonthrombogenic and substantially nonimmunogenic using an extracellular matrix coating
US5631031A (en) * 1994-06-13 1997-05-20 Meade; Thomas L. Water-insoluble amino acid salt
US5681278A (en) * 1994-06-23 1997-10-28 Cormedics Corp. Coronary vasculature treatment method
US5660873A (en) * 1994-09-09 1997-08-26 Bioseal, Limited Liability Corporaton Coating intraluminal stents
US5543430A (en) * 1994-10-05 1996-08-06 Kaesemeyer; W. H. Method and formulation of stimulating nitric oxide synthesis
US6239172B1 (en) * 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
US6425881B1 (en) * 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
US5569198A (en) * 1995-01-23 1996-10-29 Cortrak Medical Inc. Microporous catheter
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5665077A (en) * 1995-04-24 1997-09-09 Nitrosci Pharmaceuticals Llc Nitric oxide-releasing nitroso compositions and methods and intravascular devices for using them to prevent restenosis
WO1998013037A1 (en) * 1996-09-25 1998-04-02 The Regents Of The University Of California Methods of using agmatine to reduce intracellular polyamine levels and to inhibit inducible nitric oxide synthase
US6019788A (en) * 1996-11-08 2000-02-01 Gore Enterprise Holdings, Inc. Vascular shunt graft and junction for same
US6133233A (en) * 1997-02-18 2000-10-17 Kansas State University Research Foundation Peptide modulation of reperfusion injury
CN1263473A (zh) * 1997-05-21 2000-08-16 利兰·斯坦福青年大学托管委员会 增加跨生物膜转运的组合物和方法
US6231847B1 (en) * 1997-08-11 2001-05-15 Charles Larry Bisgaier Method of treating vascular proliferative responses
US6063432A (en) * 1998-05-19 2000-05-16 Cooke Pharma Arginine or lysine containing fruit healthbar formulation
US6365338B1 (en) * 1999-04-27 2002-04-02 David A. Bull Organ preservative solution containing trehalose, anti-oxidant, cations and an energy source
CA2376375C (en) * 1999-06-05 2011-07-12 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for inhibiting cardiovascular cell proliferation
US7229961B2 (en) * 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
MXPA02001857A (es) * 1999-08-24 2003-07-14 Cellgate Inc Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales.
US9135809B2 (en) * 2008-06-20 2015-09-15 At&T Intellectual Property I, Lp Voice enabled remote control for a set-top box

Also Published As

Publication number Publication date
CA2376375A1 (en) 2000-12-14
US6605115B1 (en) 2003-08-12
WO2000074701A2 (en) 2000-12-14
DE60033932T2 (de) 2007-12-06
US20060167402A1 (en) 2006-07-27
WO2000074701A3 (en) 2001-08-30
AU6119500A (en) 2000-12-28
ATE356629T1 (de) 2007-04-15
CA2376375C (en) 2011-07-12
US20040074504A1 (en) 2004-04-22
AU774185B2 (en) 2004-06-17
EP1189623B1 (de) 2007-03-14
US20100113353A1 (en) 2010-05-06
MXPA01001297A (es) 2004-01-29
JP2003501393A (ja) 2003-01-14
EP1189623A2 (de) 2002-03-27
US20060159719A1 (en) 2006-07-20
IL141250A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
ATE356629T1 (de) Methode und zusammensetzung zur inhibierung von kardiovaskulärer zellproliferation
ATE241650T1 (de) Verfahren zur herstellung von synthetischen polymerisaten mit sehr niedrigem restmonomergehalt, danach hergestellte produkte und deren verwendung
DE69433523D1 (de) Makromolekulare Mikropartikel und Verfahren zur ihrer Herstellung
EP2270042A3 (de) KDR-Peptide und Impfstoffe damit
DE60316308D1 (de) Zusammensetzungen und verfahren zur beschichtung von konservendosen
DE69815703D1 (de) Verbindungen mit leicht spaltbaren bindungen zur inaktivierung von pathogenen
CA2412505A1 (en) Composition and method for the repair and regeneration of cartilage and other tissues
DE69811666D1 (de) Behandlung metallischer oberflächen zur verbesserung ihrer bioverträglichkeit und/oder ihrer physikalischen eigenschaften
WO2000071507A3 (en) INHIBITORS OF FACTOR Xa
EA200001238A1 (ru) Непептидные ингибиторы vla-4-зависимого клеточного связывания, полезные в лечении воспалительных, аутоиммунных и респираторных заболеваний
Bottino et al. Acellular dermal matrix graft: synergistic effect of rehydration and natural crosslinking on mechanical properties
ATE445417T1 (de) Ex vivo verfahren und zusammensetzungen zur nukleinsäureverabreichung
WO1998014164A3 (de) Verwendung wasserlöslicher copolymere als wirkstoffe in kosmetischen formulierungen
NO20011283D0 (no) Anvendelse av integrin-antagonister ved behandling av multippelt myelom og myelom-indusert benresorpsjon
DE602005013981D1 (de) Pulverförmige lipasezusammensetzung und verfahren zur herstellung von verestertem produkt unter verwendung davon
FR2707992B1 (fr) Nouveaux produits organiques contenant des fonctions thiols réactives, l'un de leurs procédés de préparation et les biomatériaux les contenant.
ES8701811A1 (es) Un metodo para unir un revestimiento que contiene metal a una superficie de substrato de polimero organico
EP1548004A4 (de) Niedermolekulare biologische derivate
Gao et al. Surface immobilization of bioactive molecules on polyurethane for promotion of cytocompatibility to human endothelial cells
DE60313356D1 (de) Verwendungvon dextransulfat zur behandlung von ibmir
ATE291851T1 (de) Stückiges produkt in tiernahrungsmittelzusammensetzungen sowie ein verfahren zur herstellung desselben
ATE222122T1 (de) Verfahren zur tötung von zielzellen in geernteten zellpopulationen mit hilfe von zwei immunotoxinen
DE69803383D1 (de) Selektive inhibitoren des faktors x, eine azepinonstruktur enthaltend
DE602004016008D1 (de) Biosynthetisches implantat und seine verwendung und verfahren zur reduzierung des risikos der bildung von bindegewebe nach der implantation
DE60331825D1 (de) Verfahren für die ausgedehnte lagerung von blut und blutbestandteilen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition